Nova Mentis Life Science Corp

Nova Mentis Life Science Corp., through its subsidiaries, specializes in developing diagnostic tools and psilocybin-based therapeutic interventions for neuroinflammatory conditions. The company's primary focus in Canada is on addressing Autism Spectrum Disorder (ASD) and Fragile X Syndrome (FXS). Beyond this, Nova Mentis conducts research and development into the anti-inflammatory effects of psilocybin for metabolic indications like obesity and diabetes, and is also involved in creating various cannabis products. A notable partnership includes a research agreement with the University of Central Florida (UCF) to advance a saliva serotonin assay. Established in 2004 with its headquarters in Vancouver, Canada, the firm changed its name from Liberty Leaf Holdings Ltd. to Nova Mentis Life Science Corp. in June 2020.